Amgen Names Thomas Dittrich as Finance Chief
By Katherine Hamilton
Amgen named Thomas Dittrich, a former finance executive at the company, as its next chief financial officer.
The biotechnology company said Tuesday that Dittrich will succeed Peter Griffith, who is retiring on Aug. 31.
Griffith will retire after starting in January 2020. He will remain employed in a non-executive position from September to January to help oversee the transition.
Dittrich, 62, served in several senior finance roles at Amgen for about eight years. He left in 2014 and most recently served as chief financial officer of Galderma, a biopharmaceutical company.
Dittrich will start working with Griffith as a non-executive employee now, and will officially step into the role on Sept. 1. He will initially be based in Switzerland before relocating to Thousand Oaks, Calif.
Amgen plans to pay Dittrich an annual salary of 1.07 million Swiss francs, equal to about $1.36 million. He is also eligible to receive a one-time, two-year retention bonus of 5.8 million francs, as well as a 250,000-franc relocation allowance.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
May 19, 2026 16:51 ET (20:51 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States